The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Table 4

Sensitivity analyses based on various exclusion criteria for TRAE3-5.

Excluded trial	No. of trials	No. of patients	Experimental group	Control group	RR (95% CI)	value for RR	(%)	value for heterogeneity
Cortot (2020)	4	554	846	842	1.32 [1.04, 1.68]	<0.05	93	<0.01
Reck (2009)	4	732	626	570	1.28 [0.89, 1.84]	>0.05	93	<0.01
Reck (2010)	4	757	625	570	1.30 [0.93, 1.82]	>0.05	92	<0.01
Saito (2019)	4	597	635	563	1.11 [0.94, 1.32]	>0.05	84	<0.01
Seto (2014)	4	548	880	823	1.15 [0.93, 1.43]	>0.05	91	<0.01